EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)

Camille Richagneux, Anton Granzhan iD

ChemMedChem · 13.03.2026 · 21 (5)

DOI: 10.1002/cmdc.202500958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 09.03.2026. Verfasst von Camille Richagneux und 1 weiteren Autor:innen. Beteiligte Einrichtung: CMBC, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, Orsay, France. Hauptthemen laut MEDLINE: Myotonic Dystrophy, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotonic dystrophy type 1 (DM1) is caused by expanded CTG repeats, d(CTG) exp , transcribed into toxic r(CUG) exp RNA repeats that sequester splicing regulator MBNL1, leading to its loss‐of‐function. An emerging therapeutic strategy toward DM1 treatment relies on the inhibition of MBNL1 sequestration by using small molecules, oligomers, peptides, engineered proteins, or synthetic oligonucleotides that interact with CUG repeats at the RNA level and/or CTG repeats at the DNA level. This review covers ∼18 years of research in the field of CUG and CTG ligands that were identified or rationally designed as DM1 drug candidates, with an emphasis on their chemical structures, molecular design, RNA‐ or DNA‐binding modes, in vitro affinities and specificities, molecular mechanisms of action, and biological activity in DM1 models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyRNA-Binding ProteinsHumans

Stichwörter der Autor:innen

CTG repeatsCUG repeatsMBNL1RNA degradersRNA ligandsmyotonic dystrophy type 1

Substanzen

RNA-Binding ProteinsMBNL1 protein, human

Autor:innen und Institutionen

  • CMBC, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, Orsay, France.
  • LCBPT, CNRS UMR8601, Université Paris Cité, Paris, France.

ORCID-Profile: Anton Granzhan

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Richagneux, C., & Granzhan, A. (2026). Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). ChemMedChem, 21(5). https://doi.org/10.1002/cmdc.202500958

Vancouver

Richagneux C, Granzhan A. Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). ChemMedChem. 2026;21(5). doi:10.1002/cmdc.202500958

BibTeX
@article{Richagneux2026,
  author = {Richagneux, Camille and Granzhan, Anton},
  title = {Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {5},
  doi = {10.1002/cmdc.202500958}
}
Kostenlos starten →